1. Home
  2. LXFR vs MNPR Comparison

LXFR vs MNPR Comparison

Compare LXFR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Luxfer Holdings PLC

LXFR

Luxfer Holdings PLC

HOLD

Current Price

$19.23

Market Cap

421.4M

Sector

Industrials

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$67.64

Market Cap

368.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXFR
MNPR
Founded
1898
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.4M
368.9M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
LXFR
MNPR
Price
$19.23
$67.64
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$107.00
AVG Volume (30 Days)
133.4K
109.3K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
3.65%
N/A
EPS Growth
N/A
54.99
EPS
0.13
N/A
Revenue
$384,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.01
N/A
P/E Ratio
$146.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.19
$29.18
52 Week High
$19.25
$105.00

Technical Indicators

Market Signals
Indicator
LXFR
MNPR
Relative Strength Index (RSI) 78.91 68.77
Support Level $11.64 $56.02
Resistance Level N/A $76.13
Average True Range (ATR) 0.71 3.12
MACD 0.06 0.65
Stochastic Oscillator 86.64 94.63

Price Performance

Historical Comparison
LXFR
MNPR

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: